On Tuesday, Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), gained 0.15% to $6.62.
Spectrum Pharmaceuticals, declared publication of results from the pivotal clinical study for EVOMELA, used for myeloablative conditioning in multiple myeloma (MM) patients undergoing autologous transplantation. (ASCT). The study, led by Dr. Parameswaran Hari from Froedtert Hospital and Medical College of Wisconsin, was published in the Biology of Blood and Marrow Transplantation (BBMT) journal.
“We are happy to have these clinical data selected for publication in the BBMT journal,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “These study data confirm the efficacy and acceptable safety profile of EVOMELA as a high-dose conditioning regimen for ASCT in patients with MM. Our novel EVOMELA formulation uses Captisol to improve the solubility and stability of Melphalan, and has eliminated the need for a propylene glycol-containing cosolvent. Importantly, this allows for longer use and infusion times with EVOMELA, which potentially simplifies its clinical use and administration logistics. Instead of propylene glycol, which is associated with toxicities counting renal dysfunction and arrhythmias, this new formulation uses a standard aqueous diluent for reconstitution. We look forward to FDA’s NDA decision on EVOMELA in October. Spectrum continues to deliver on its commitment to develop improved cancer therapies that benefit patients and health care providers.”
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
Shares of Ameriprise Financial, Inc. (NYSE:AMP), inclined 0.84% to $109.84, during its last trading session.
Ameriprise Financial is matching public donations to Feeding America–up to$500,000– in support of Hunger Action MonthTM. As part of the Ameriprise Financial Challenge, individuals can double the impact of their gift to Feeding America, the nation’s leading domestic hunger-relief organization, ahead of the busy holiday season.* When combined with the Ameriprise gift, every dollar donated now through Thanksgiving can have twice the impact. That means together we can assist provide 11 million meals to families facing hunger in the U.S. through the Feeding America network of food banks.
“Despite the improving economy, many Americans continue to struggle with putting food on the table,” said Brian Pietsch, head of community relations at Ameriprise Financial. “Feeding America and its member food banks are a critical source of support and strength for these families. We encourage anyone who is in a position to donate to have their contribution matched by Ameriprise.”
Ameriprise began a charitable partnership with Feeding America in 2009 with the aim to assist meet an raised demand on food banks and work toward finding long-term solutions to domestic hunger. Together with its advisors, employees and volunteers, Ameriprise has offered more than 40 million meals and volunteered more than 130,000 hours to support hunger-relief organizations nationwide.
Ameriprise Financial, Inc., through its auxiliaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The company’s Advice & Wealth Administration segment provides financial planning and advice, in addition to full-service brokerage services primarily to retail clients through its advisors.
At the end of Tuesday’s trade, Shares of Avis Budget Group Inc. (NASDAQ:CAR), gained 3.50% to $45.55.
Avis Budget Group, the exclusive car rental provider for AARP members, encourages travelers 50-and-over to take advantage of the many benefits of Fall travel, counting cooler temperatures, lower prices, the less-congested roadways and the smaller crowds at popular attractions.
Avis Budget Group provides AARP members with discounted rates and special offers on vehicle rentals with Avis Car Rental, Budget Car Rental and Payless Car Rental. In addition, AARP members can save on their annual membership fee with Zipcar, the world’s leading car sharing network.
“For many people, traveling after Labor Day is the ideal time to get away and enjoy milder weather and lower prices on travel,” said Beth Kinerk, senior vice president of sales, Avis Budget Group. “As the exclusive car rental provider for AARP members, Avis Budget Group provides access to convenient and affordable transportation so that AARP members can stretch their travel budget even further to make lasting memories.”
Avis Budget Group, Inc., together with its auxiliaries, provides car and truck rentals, car sharing, and ancillary services to businesses and consumers worldwide. The company has three segments: North America, International, and Truck Rental.
Finally, Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), ended its last trade with 3.05% gain, and closed at $5.06.
Threshold Pharmaceuticals, declared the appointment of Mark Hopkins, J.D., Ph.D., as Vice President of Intellectual Property and Assistant General Counsel. In this newly created position, Dr. Hopkins will oversee worldwide intellectual property strategy and activities related to further advancement of Threshold’s intellectual property portfolio for its investigational anti-cancer therapeutics, evofosfamide and tarloxotinib bromide*, and hypoxia-activated prodrug technology. Dr. Hopkins will also be responsible for oversight of corporate legal matters at Threshold.
Dr. Hopkins joins Threshold with more than 16 years of legal experience in the pharmaceutical industry. Preceding to joining Threshold, Dr. Hopkins was a partner at Kilpatrick Townsend and Stockton LLP where he led a team of legal professionals providing legal opinions and securing patents for pharmaceutical companies on their key drugs and technologies.
Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
